|
CN109563156A
|
|
The anti-HSV synergistic activity of antibody and antivirotic
|
|
CN109310832A
|
|
Spray Dispenser
|
|
EP3081212A1
|
|
Carboxymethylcysteine for topical treatment of stretch marks
|
|
EP3050897A1
|
|
Human monoclonal antibodies endowed with strong neutralizing activity against HSV-1 and HSV-2
|
|
WO2016112977A1
|
|
Di-pidotimod benzathine and solid forms thereof
|
|
US2015064126A1
|
|
Use of chitosans for the treatment of nail inflammatory diseases
|
|
EP2910245A1
|
|
Topical antifungal composition for treating onychomycosis
|
|
EP2845597A1
|
|
Hydroxypropyl chitosan for the treatment of onychomycosis
|
|
WO2015036009A1
|
|
Pidotimod for use in the treatment of inflammation-associated diseases
|
|
EP2845591A1
|
|
Use of trifluoroacetic acid as keratolytic agent to treat hyperkeratotic skin lesions
|
|
EP2835130A1
|
|
Composition for skin anti-ageing treatment
|
|
US8697753B1
|
|
Method of treating onychomycosis
|
|
EP2796135A1
|
|
Use of trifluoroacetic acid and salts thereof to treat hypercholesterolemia
|
|
GEP201706683B
|
|
Usage of pidotimod to treat inflammatory bowel diseases
|
|
MX2015014060A
|
|
Use of pidotimod to treat irritable bowel syndrome.
|
|
WO2014161595A1
|
|
Use of pidotimod to treat inflammatory bowel disease
|
|
GEP201706684B
|
|
Usage of pidotimod to treat irritable bowel syndrome
|
|
CN104797254A
|
|
Use of pidotimod to treat atopic dermatitis
|
|
BR112015011391A2
|
|
use of pidotimod to treat psoriasis
|
|
EP2662371A1
|
|
(R)-Nifuratel and synthesis of (R) and (S)-Nifuratel
|
